GHK-Cu (Copper Peptide) at a glance
A fast read for beginners, with evidence strength, route context, safety depth, and community activity surfaced before the deeper sections.
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide first isolated from human plasma by Loren Pickart in 1973. It is present in high concentrations in plasma, saliva, and urine in youth, declining significantly with age - a pattern that correlates with the broader decline in wound healing and tissue maintenance capacity.
GHK-Cu acts as a biological signal that activates tissue remodeling and repair. It upregulates collagen, elastin, and glycosaminoglycan synthesis; promotes angiogenesis; and reduces inflammation. Critically, it also activates the removal of damaged proteins and abnormal collagen via matrix metalloproteinases (MMPs), allowing for genuine tissue remodeling rather than simple scar formation.
Beyond skin applications, GHK-Cu has demonstrated broad gene-regulatory effects, modulating hundreds of genes involved in inflammation, DNA repair, neurological protection, and cancer suppression. Its safety profile is excellent across decades of topical use, and growing evidence supports systemic applications via injection for tissue repair and anti-aging.
Key Benefits
Saves this peptide to your Watchlist and helps you find new research, news, and questions later.